KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42225101无 PMCID2026-Jun0.95The record is a phase III randomized, double-blind, placebo-controlled trial in human oncology (prostate cancer) with a drug-containing intervention (aglatimagene besadenovec plus valacyclovir) and a primary time-to-event efficacy endpoint (disease-free survival). It meets all eligibility criteria for the oncology KM digitization cohort.无 KM 图
Dietary inflammatory index and unfavorable dietary patterns associated with ischemic stroke in China.Asia Pac J Clin NutrPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42242853PMC132364452026-Jun0.95The study is a randomized Phase III trial in oncology patients with a primary efficacy endpoint, but the endpoint is a change in a nutritional biomarker (pre-albumin), not a time-to-event outcome like OS or PFS. The intervention is a nutritional formula, not a drug, and there is no Kaplan-Meier analysis or hazard ratio. Therefore, it does not meet the criteria for inclusion in an oncology Kaplan-Meier digitization cohort.无 KM 图
Baclofen Modulates Neural Intrinsic Functional Connectivity in Treatment-Seeking Individuals With Alcohol Use Disorder.Alcohol Clin Exp Res (Hoboken)已检查 1 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other。PMID 42246466PMC132384372026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Progression to Wheelchair in Secondary Progressive Multiple Sclerosis and Impact of Siponimod: Post Hoc Analyses From the EXPAND Study.Eur J NeurolPMID 42257510PMC132446612026-Jun0.98未发现恶性肿瘤人群证据。部分完成
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.Alzheimers Dement疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。PMID 42273802PMC132546822026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).JCO Glob Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42308452无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
A Randomized Controlled Phase 3 Trial of Oral Prednisolone Administration Versus Local Triamcinolone Injection Therapy for Esophageal Stricture Prevention After Extensive Endoscopic Submucosal Dissection (JCOG1217).Dig Endosc疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 km;FIGURE 3:AI 判定为 multi panel km。PMID 42313516PMC132779632026-Jun0.85While this is a Phase III randomized oncology trial with drug interventions and a time-to-event endpoint (stricture-free survival), the primary endpoint is prevention of a post-procedural complication (esophageal stricture), not a direct oncology efficacy endpoint for the malignant neoplasm itself. Therefore, it does not meet the specific requirement for a primary/key secondary oncology efficacy endpoint (OS, PFS, DFS, etc.).无 KM 图
Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.Cancer Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:非 KM 图。PMID 42339511PMC132918022026-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.Health Technol AssessPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42370465无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Plain balloon angioplasty +/- bare metal stenting versus drug-coated balloon angioplasty +/- bare metal stenting versus primary drug-eluting stenting in patients with chronic limb-threatening ischaemia: BASIL-3, an open-label, three-arm, randomised, multi-centre, phase 3 trial.Health Technol Assess疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42381494PMC133344172026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41865758无 PMCID2026-May-300.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42208560无 PMCID2026-May-300.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42208561无 PMCID2026-May-300.98未发现恶性肿瘤人群证据。无 KM 图
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42202319无 PMCID2026-May-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.Clin Exp DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41206702无 PMCID2026-May-260.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of clobetasol propionate ophthalmic nanoemulsion for treating intraocular inflammation and pain associated with cataract surgery: two phase 3 multicentre, randomised, placebo-controlled, double-masked clinical studies.BMJ Open已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 multi panel km;另有 1 张未列出。PMID 42192627PMC132021012026-May-240.98未发现恶性肿瘤人群证据。无 KM 图
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42150581无 PMCID2026-May-230.98未发现恶性肿瘤人群证据。无 KM 图
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42000149无 PMCID2026-May-220.98未发现恶性肿瘤人群证据。无 KM 图
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.Signal Transduct Target TherPMID 42168151PMC131947362026-May-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.Acta Derm VenereolPMID 42163822PMC131912192026-May-210.98未发现恶性肿瘤人群证据。已完成
Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.Lupus Sci Med已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。PMID 42167880PMC132020722026-May-210.98未发现恶性肿瘤人群证据。无 KM 图
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old.Clin Infect Dis已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。PMID 41560517PMC131896522026-May-200.98未发现恶性肿瘤人群证据。无 KM 图
Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.J Clin OncolPMID 41564372PMC131857292026-May-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::森林图/亚组分析图;Figure 4::非 KM 图。PMID 41616224PMC128669542026-May-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.J Clin OncolAI 判定该论文不进入自动 KM 提取:The record is explicitly described as a Phase II trial.PMID 42018958无 PMCID2026-May-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
Topical clobetasol propionate 0.025% oral gel in the treatment of oral lichen planus: a double-blind, randomized placebo-controlled trial.BMC Oral Health入排复审未纳入:未发现恶性肿瘤人群证据。PMID 42163196PMC132176722026-May-200.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial.Br J DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41697953无 PMCID2026-May-190.98未发现恶性肿瘤人群证据。无 KM 图
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42018318PMC131038812026-May-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.J Am Heart Assoc已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。PMID 42132192PMC132795512026-May-190.98未发现恶性肿瘤人群证据。无 KM 图
Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study.Ann Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42154070无 PMCID2026-May-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults.Aesthet Surg J已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 1 张未列出。PMID 41692601PMC131829032026-May-180.98未发现恶性肿瘤人群证据。无 KM 图
Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42114550无 PMCID2026-May-160.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42134354无 PMCID2026-May-160.98未发现恶性肿瘤人群证据。无 KM 图
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42134356无 PMCID2026-May-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Feasibility, acceptability and efficacy of a nurse-led palliative care health coaching intervention (Educate, Nurture, Advise before Life Ends) for patients with heart failure and their caregivers in Singapore: a randomised wait-list controlled pilot study of health coaching in Asian heart failure.BMJ Open入排复审未纳入:未发现恶性肿瘤人群证据。PMID 42152453PMC131824252026-May-150.98未发现恶性肿瘤人群证据。无 KM 图
A Phase 3 Trial of Brepocitinib in Dermatomyositis.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41910335无 PMCID2026-May-140.98未发现恶性肿瘤人群证据。无 KM 图
Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42127390无 PMCID2026-May-140.98未发现恶性肿瘤人群证据。无 KM 图
Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42127391无 PMCID2026-May-140.85The study is a Phase III randomized trial of a drug intervention in humans with original results, but it investigates IgA nephropathy (a kidney disease), not a human malignant neoplasm. Additionally, the primary endpoint is a change in proteinuria (protein-to-creatinine ratio), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.无 KM 图
Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial.BMJ疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig 1:图注未提示 KM 曲线;Fig 2:森林图/亚组分析图。PMID 42128454PMC131700712026-May-130.98未发现恶性肿瘤人群证据。无 KM 图
Single-Pill Low-Dose Triple Combination Therapy vs Standard-Dose Monotherapy in Patients With Mild-to-Moderate Hypertension.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41670573无 PMCID2026-May-120.98未发现恶性肿瘤人群证据。无 KM 图
Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41984450PMC130845532026-May-120.98未发现恶性肿瘤人群证据。无 KM 图
Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.J Natl Compr Canc NetwPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42119607无 PMCID2026-May-120.95This is an original Phase III randomized trial in human oncology patients with a drug intervention, but its primary efficacy endpoint is a pain score (NRS), not a time-to-event outcome like OS, PFS, or DFS. There is no mention of Kaplan-Meier analysis or hazard ratios for such endpoints.无 KM 图
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.J Clin OncolPMID 41894648PMC131660722026-May-100.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42102826无 PMCID2026-May-090.90The study is a randomized, population-based, Phase III trial in colorectal cancer prevention, but the intervention is colonoscopy screening (non-drug). The primary endpoints are cancer incidence and mortality as risk ratios, not time-to-event outcomes like OS, PFS, DFS, etc., or Kaplan-Meier/HR results. Therefore, it does not meet the required criteria for a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.无 KM 图
Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41910380无 PMCID2026-May-070.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42090792无 PMCID2026-May-070.98未发现恶性肿瘤人群证据。无 KM 图
Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42090793无 PMCID2026-May-070.98未发现恶性肿瘤人群证据。无 KM 图
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.Rheumatology (Oxford)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1:图注未提示 KM 曲线;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。PMID 41838419PMC131988802026-May-050.98未发现恶性肿瘤人群证据。无 KM 图
NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials.Nat Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:图注未提示 KM 曲线;Fig. 3:图注未提示 KM 曲线;Fig. 4:图注未提示 KM 曲线。PMID 42082491PMC133425652026-May-040.98未发现恶性肿瘤人群证据。无 KM 图
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41855781无 PMCID2026-May-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图